News
-
-
COMMUNIQUÉ DE PRESSE
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and coexisting asthma, showing superior efficacy across all key endpoints in a phase 4 study presented at EAACI -
COMMUNIQUÉ DE PRESSE
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
New to The Street premieres Episode #671 featuring dynamic companies across blockchain, AI, health tech, wellness, and pharmaceutical sectors. Sponsored by The Sustainable Green Team's Waterless Garden and PetVivo Holdings, Inc.'s SPRYNG™ product -
COMMUNIQUÉ DE PRESSE
SAFE - Lancement d’une réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions sous condition suspensive de la réalisation des opérations de regroupement d’actions
Lancement d’une réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions sous condition suspensive de la réalisation des opérations de regroupement d’actions -
COMMUNIQUÉ DE PRESSE
Battery X Metals Validates Provisional Patent Applications Filed with the United States Patent and Trademark Office Through Successful Real-World Trials of Next-Generation Lithium-Ion Battery Rebalancing Machine
Battery X Rebalancing Technologies achieves 100% recovery of imbalance-related capacity in Nissan Leaf & recovers 37.7% of Rated Capacity in Class 3 commercial EV battery pack. Validation trials support pending USPTO patent applications & position as EV battery reconditioning market leader -
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
Onco-Innovations partners with University of Alberta and Cross Cancer Institute for preclinical study focusing on hard-to-treat cancers, starting with glioblastoma. Research led by Dr. Michael Weinfeld -
